Certificate of Pharmaceutical Product (CoPP) – general and country specific MCQs With Answer

Introduction: Certificate of Pharmaceutical Product (CoPP) – general and country specific MCQs With Answer is a focused practice resource for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics. This blog provides concise MCQs covering the purpose, content, format and practical use of CoPPs in global pharmaceutical trade. Questions explore how CoPPs relate to marketing authorization, GMP status, WHO formats, validity, legalization/apostille, and country-specific expectations. Emphasis is given to real regulatory scenarios, differences between CoPP and other certificates, and limitations when relying on CoPP for registration. Use these questions to sharpen interpretation of regulatory documents and to prepare for viva, exams, and regulatory dossier preparation.

Q1. What is the primary purpose of a Certificate of Pharmaceutical Product (CoPP)?

• A marketing authorization dossier for the importing country
• A document issued by a competent authority declaring the product’s marketing status and GMP compliance in the exporting country
• A detailed stability report for the finished product
• A manufacturer’s internal batch release certificate

Correct Answer: A document issued by a competent authority declaring the product’s marketing status and GMP compliance in the exporting country

Q2. Who normally issues a Certificate of Pharmaceutical Product?

• The manufacturer’s Quality Assurance (QA) head
• An independent third-party laboratory
• The competent national drug regulatory authority of the exporting country
• The importing country’s regulatory authority

Correct Answer: The competent national drug regulatory authority of the exporting country

Q3. Which international scheme historically provided the standard CoPP format widely used by many countries?

• ICH Common Technical Document (CTD) scheme
• EU Mutual Recognition Agreement
• WHO Certification Scheme for Pharmaceutical Products (1988)
• GMP Harmonization Treaty (2005)

Correct Answer: WHO Certification Scheme for Pharmaceutical Products (1988)

Q4. Which of the following items is NOT typically included within a CoPP?

• Marketing authorization number and status
• Manufacturer name and address
• Detailed batch release test results and individual batch numbers
• Date of issue and signature of competent authority

Correct Answer: Detailed batch release test results and individual batch numbers

Q5. How does a CoPP differ from a Free Sale Certificate (FSC)?

• CoPP confirms free sale; FSC confirms GMP compliance
• CoPP asserts registration and GMP compliance; FSC only confirms that the product is sold freely in the exporting country
• There is no difference; both are identical documents
• FSC is issued by the importing country while CoPP is issued by WHO

Correct Answer: CoPP asserts registration and GMP compliance; FSC only confirms that the product is sold freely in the exporting country

Q6. Is there a universal validity period for CoPPs accepted globally?

• Yes — all CoPPs are valid for exactly 5 years
• Yes — all CoPPs are valid until the product expires
• No — there is no standardized global validity; validity depends on the issuing authority
• Yes — CoPPs are valid for 1 year only

Correct Answer: No — there is no standardized global validity; validity depends on the issuing authority

Q7. Which additional document is most commonly requested together with a CoPP when a manufacturer files for registration in another country?

• Certificate of Good Manufacturing Practice (GMP) / GMP inspection certificate
• Original production batch samples
• Full clinical study patient records
• Manufacturer’s marketing strategy

Correct Answer: Certificate of Good Manufacturing Practice (GMP) / GMP inspection certificate

Q8. In CoPP terminology, what does the entry “marketed” indicate?

• The product is under clinical trials only
• The product is authorized and sold in the issuing country
• The product has been discontinued globally
• The product is expired and recalled

Correct Answer: The product is authorized and sold in the issuing country

Q9. Who signs and authenticates the CoPP?

• The company’s Chief Executive Officer (CEO)
• A designated official of the competent regulatory authority (e.g., registrar/director)
• The head of the importing country’s customs department
• The head of the manufacturing plant’s production department

Correct Answer: A designated official of the competent regulatory authority (e.g., registrar/director)

Q10. Legalization or apostille of a CoPP is typically carried out by which entity when required by the importing country?

• The issuing national competent authority or its designated apostille office followed by the importing country’s embassy/consulate if required
• The manufacturer alone without any authority involvement
• The World Health Organization
• The importing country’s customs at the point of entry only

Correct Answer: The issuing national competent authority or its designated apostille office followed by the importing country’s embassy/consulate if required

Q11. Which CoPP statement is used when a product is produced for export but not sold in the issuing country?

• “Marketed and sold domestically”
• “For clinical trials only”
• “Not marketed / Export only”
• “Withdrawn from market”

Correct Answer: “Not marketed / Export only”

Q12. What major change regarding the WHO CoPP scheme should regulatory students be aware of since 2019?

• WHO upgraded the scheme to mandate electronic CoPPs worldwide
• WHO discontinued the global Certification Scheme in 2019, leading to increased reliance on national CoPPs and bilateral/regional arrangements
• WHO made CoPP compulsory for all exports of veterinary products only
• WHO began issuing CoPPs directly for all manufacturers

Correct Answer: WHO discontinued the global Certification Scheme in 2019, leading to increased reliance on national CoPPs and bilateral/regional arrangements

Q13. Which of the following is generally NOT a component of the standard CoPP format?

• Approved therapeutic indications
• Marketing authorization holder name
• Detailed manufacturing batch protocols and in-house test methods
• Date of issue and issuing authority signature

Correct Answer: Detailed manufacturing batch protocols and in-house test methods

Q14. Can a Certificate of Pharmaceutical Product (CoPP) alone substitute for a full regulatory dossier when applying to a stringent regulatory authority (SRA)?

• Yes — SRAs accept CoPP as the only requirement
• No — SRAs generally require a full dossier and do not rely solely on CoPP
• Yes — but only for biological medicines
• Yes — if the CoPP is issued by WHO directly

Correct Answer: No — SRAs generally require a full dossier and do not rely solely on CoPP

Q15. Which Indian authority is responsible for issuing CoPPs for products exported from India?

• Indian Pharmacopoeia Commission (IPC)
• Central Drugs Standard Control Organization (CDSCO)
• Food Safety and Standards Authority of India (FSSAI)
• National Institute of Biologicals (NIB)

Correct Answer: Central Drugs Standard Control Organization (CDSCO)

Q16. Can a CoPP replace a separate GMP certificate for import purposes?

• Yes — CoPP is legally a substitute for any GMP certificate worldwide
• No — CoPP does not replace a dedicated GMP certificate; importing authorities may still request a separate GMP certificate or inspection report
• Yes — but only when signed by the manufacturer
• No — CoPP replaces batch release certificates but not GMP certificates

Correct Answer: No — CoPP does not replace a dedicated GMP certificate; importing authorities may still request a separate GMP certificate or inspection report

Q17. Which of the following is a recognised limitation of relying on CoPP during product registration?

• CoPP provides exhaustive stability and batch-by-batch quality data
• CoPP confirms therapeutic equivalence across brands
• CoPP does not provide detailed analytical, stability or batch analysis data necessary for technical assessment
• CoPP guarantees immediate marketing approval in the importing country

Correct Answer: CoPP does not provide detailed analytical, stability or batch analysis data necessary for technical assessment

Q18. Which group of countries most commonly continues to request CoPPs (often in WHO format or national variant) as part of their import or registration requirements?

• Many low- and middle-income countries, including several African, some Asian and Latin American nations
• All European Union member states exclusively
• Only the United States and Canada
• Antarctica and arctic territories

Correct Answer: Many low- and middle-income countries, including several African, some Asian and Latin American nations

Q19. Is it possible for a regulatory authority to issue a CoPP indicating the product is “for export only” even if it is not marketed domestically?

• No — CoPP can only be issued for products sold domestically
• Yes — many authorities can issue a CoPP that explicitly states the product is not marketed domestically and is for export only
• No — CoPPs are only issued by WHO for marketed products
• Yes — but only if the product has already been registered in the importing country

Correct Answer: Yes — many authorities can issue a CoPP that explicitly states the product is not marketed domestically and is for export only

Q20. Which prerequisites are typically verified by the issuing authority before granting a CoPP?

• Marketing authorization in the issuing country and confirmation of GMP compliance at the manufacturing site
• Only the company’s marketing plan for the importing country
• Only the product label artwork design
• The importing country’s clinical trial approvals

Correct Answer: Marketing authorization in the issuing country and confirmation of GMP compliance at the manufacturing site

Download